This site is intended for Healthcare Professionals only.

AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial

Date:

Share post:

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.

The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab – the existing standard of care – improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.

Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.

Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: “DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I’m grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community.”

Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: “While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this  this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups.”

The company added that safety and tolerability of these combinations were broadly consistent with that observed in prior clinical trials and the known profiles of the individual medicines.

The data will be presented at forthcoming medical meetings and shared with health authorities, it added.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Phlo Pharmacy secures £9 Million in funding amidst challenging investor climate

Phlo's pharmacy integrated digital healthcare ecosystem revolutionizes patient care across multiple platform Phlo Digital Pharmacy, a leading digital healthcare...

Another wake-up call! Nuffield Trust report warns patients face ‘new normal’ of medicine shortages

Community Pharmacy England has already warned that medicine shortages and market instability are “at the worst that pharmacies...

NHS supply chain appoints Richard Evans as commercial executive director

Experienced leader to drive transformation in healthcare supply chain through new NHS  appointment NHS Supply Chain today announced the...

UK launches Critical Imports Council to secure supplies of medicines, smartphone chips

The Council aims to address the supply challenges businesses face and develop real-life solutions The UK government has...